Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.
Ravi A. Madan(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Amy Hankin(National Institutes of Health), Laura A. Sena(Johns Hopkins University), Marijo Bilušić(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), Megan Hausler(National Institutes of Health), Liza Lindenberg(National Cancer Institute), Russell K. Pachynski, Monique Williams(National Institutes of Health), Melissa L. Abel(National Institutes of Health), Helen Moon(National Cancer Institute), Edwin M. Posadas(Cedars-Sinai Medical Center)
Cited by 2
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
American Cancer Society prostate cancer survivorship care guidelines
|CA A Cancer Journal for Clinicians|2014|402